Attention Deficit Hyperactivity Disorder (ADHD): characteristics, diagnosis and treatment with methylphenidate

Authors

DOI:

https://doi.org/10.18378/rebes.v13i3.10106

Abstract

Attention deficit hyperactivity disorder (ADHD) is a neurobehavioral disorder that usually arises during childhood, with prevalence estimates ranging from 2 to 18% globally and three times higher in males than in females. The diagnosis of ADHD is confirmed by recognizing excessive inattention, hyperactivity and impulsivity in a child, before the age of 12, which impair their functioning or development, while current treatments include pharmacological, psychotherapeutic and psychoeducational interventions. In this sense, the aim is to discuss the characteristics and diagnosis, as well as to explore treatment with methylphenidate in ADHD symptoms, addressing the beneficial and harmful effects of the drug. The methodology is a bibliographical study, of the exploratory type with a qualitative approach, which aims to organize ideas in the following stages (formulating the problem, choosing the topic to be investigated, drawing up the work plan, formulating the objectives, identifying, locating and obtaining sources that are capable of providing the appropriate data for the desired research, reading the material obtained, logical analysis and interpretation of the data and final writing of the text).  Finally, it can be concluded that the main symptoms of ADHD include inattention, hyperactivity and impulsivity, but they are not exclusive to the disorder. One of the major challenges is the substantial impact on individuals throughout their lives, highlighting the importance of identifying and addressing this condition in childhood. Effective management of ADHD symptoms in adults and children can mitigate the detrimental effects of the disorder on various aspects of daily functioning and mental well-being. Methylphenidate has emerged as a viable treatment option; however, it is important to recognize that its use carries potential risks and considerations.

Downloads

Download data is not yet available.

References

ABDA. Associação Brasileira do Déficit de Atenção. Tratamento [Internet]. Rio de Janeiro: ABDA; p. 1, 2017.

AMERICAN PSYCHIATRIC ASSOCIATION. Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; DSM5-TR; American Psychiatric Association: Washington, DC, USA, 2022.

ASTELLANOS, F. X. et al. Characterizing cognition in ADHD: beyond executive dysfunction. Trends in cognitive sciences, v. 10, n. 3, p. 117-123, 2006.

BIEŚ, R. et al. The Risk of Methylphenidate Pharmacotherapy for Adults with ADHD. Pharmaceuticals, v. 16, n. 9, p. 1292, 2023.

BLOCK, S. L. Attention-deficit disorder: A paradigm for psychotropic medication intervention in pediatrics. Pediatric Clinics of North America, v. 45, n. 5, p. 1053-1083, 1998.

CARDANO, M. Manual de pesquisa qualitativa. A contribuição da teoria da argumentação. Tradução: Elisabeth da Rosa Conill. Petrópolis, Rio de Janeiro: Vozes, 2017.

CHERLAND, E.; FITZPATRICK, R. Psychotic side effects of psychostimulants: a 5-year review. The Canadian Journal of Psychiatry, v. 44, n. 8, p. 811-813, 1999.

DALRYMPLE, R. A. et al. NICE guideline review: Attention deficit hyperactivity disorder: diagnosis and management (NG87). Archives of disease in childhood-education and practice, v. 105, n. 5, p. 289-293, 2020.

ERCAN, E. S. et al. Prevalence and diagnostic stability of ADHD and ODD in Turkish children: a 4-year longitudinal study. Child and adolescent psychiatry and mental health, v. 7, p. 1-10, 2013.

FDA. US Food, Drug Administration. Communication about an ongoing safety review of stimulant medications used in children with attention‐deficit/hyperactivity disorder (ADHD). http://1.usa.gov/1M5AYoq

GIL, A. C. Como elaborar projetos de pesquisa. 4. ed. São Paulo: Atlas, 2007.

GIL, A. C. et al. Como elaborar projetos de pesquisa. São Paulo: Atlas, 2002.

GILMORE, K. A Psychoeducational and Support Group for Parents of ADD/ADHD Children. Perspectives In Learning, v. 2, n. 1, p. 7, 2001.

HUSS, M. et al. Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial. Advances in therapy, v. 31, p. 44-65, 2014.

JONES, M. N.; WEBER, K. P.; MCLAUGHLIN, T. F. No Teacher Left Behind: Educating Students with ASD and ADHD in the Inclusion Classroom. Journal of Special Education Apprenticeship, v. 2, n. 2, p. n2, 2013.

KADESJÖ, B. ADHD hos barn och vuxna. Socialstyr., 2002.

KANJWAL, K. et al. Use of methylphenidate in the treatment of patients suffering from refractory postural tachycardia syndrome. American journal of therapeutics, v. 19, n. 1, p. 2-6, 2012.

KESSLER, R. C. et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. American Journal of psychiatry, v. 163, n. 4, p. 716-723, 2006.

LIOTTI, M. et al. Correlatos eletrofisiológicos da inibição da resposta em crianças e adolescentes com TDAH: influência do sexo, idade e história de tratamento anterior. Psicofisiologia, v. 44, n. 6, pág. 936-948, 2007.

MAGNUS, W.; NAZIR, S.; ANILKUMAR, A. C.; SHABAN, K. Attention Deficit Hyperactivity Disorder. In StatPearls. 2022.

MAHONE, E. M.; DENCKLA, M. B. Attention-deficit/hyperactivity disorder: a historical neuropsychological perspective. Journal of the International Neuropsychological Society, v. 23, n. 9-10, p. 916-929, 2017.

MTA. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of general psychiatry, v. 56, n. 12, p. 1073-1086, 1999.

NAZAROVA, V. A. et al. Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials. Frontiers in Pharmacology, v. 13, p. 1066988, 2022.

NICE. NATIONAL COLLABORATING CENTRE FOR MENTAL HEALTH (UK et al. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. 2009.

NIGG, J. T.; CASEY, B. J. An integrative theory of attention-deficit/hyperactivity disorder based on the cognitive and affective neurosciences. Development and psychopathology, v. 17, n. 3, p. 785-806, 2005.

PASINI, A. et al. Attention and executive functions profile in drug naive ADHD subtypes. Brain and Development, v. 29, n. 7, p. 400-408, 2007.

REIMHERR, F. W. et al. Emotional dysregulation in adult ADHD and response to atomoxetine. Biological psychiatry, v. 58, n. 2, p. 125-131, 2005.

SANDER, D.; SANDER, D.; NUMMENMAA, L. Reward and emotion: an affective neuroscience approach. Current Opinion in Behavioral Sciences, v. 39, p. 161-167, 2021.

SERGEANT, J. A. et al. The top and the bottom of ADHD: a neuropsychological perspective. Neuroscience & Biobehavioral Reviews, v. 27, n. 7, p. 583-592, 2003.

SHAW, P. et al. Emotion dysregulation in attention deficit hyperactivity disorder. American Journal of Psychiatry, v. 171, n. 3, p. 276-293, 2014.

SKALIDOU, S.; ANESTIS, A.; BAKOLAS, N.; TSOULFA, G.; PAPADIMITRIOU, K. Swimming Activity Alleviates the Symptoms of Attention Deficit Hyperactivity Disorder (ADHD): A Case Report. Healthcare, v. 11, p. 1999, 2023.

SKOGLI, E. W. et al. ADHD in girls and boys–gender differences in co-existing symptoms and executive function measures. BMC psychiatry, v. 13, n. 1, p. 1-12, 2013.

SMITH, B. H. et al. The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/hyperactivity disorder (ADHD). Clinical child and family psychology review, v. 3, p. 243-267, 2000.

STEVENSON, R. D.; WOLRAICH, M L. Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder. Pediatric Clinics of North America, v. 36, n. 5, p. 1183-1197, 1989.

SWANSON, J. et al. Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of Children with ADHD (MTA) Part I: Executive Summary. Journal of Attention Disorders, v. 12, n. 1, p. 4-14, 2008.

VAN DE LOO-NEUS, G. H. H.; ROMMELSE, N.; BUITELAAR, J. K. To stop or not to stop? How long should medication treatment of attention-deficit hyperactivity disorder be extended?. European Neuropsychopharmacology, v. 21, n. 8, p. 584-599, 2011.

VITIELLO, B. Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child and adolescent psychiatric clinics of North America, v. 17, n. 2, p. 459-474, 2008.

YOUNG, S. et al. Females with ADHD: An expert consensus statement taking a lifespan approach providing guidance for the identification and treatment of attention-deficit/hyperactivity disorder in girls and women. BMC psychiatry, v. 20, n. 1, p. 1-27, 2020.

ZOCCOLILLO, M. Gender and the development of conduct disorder. Development and psychopathology, v. 5, n. 1-2, p. 65-78, 1993.

Published

2023-09-19

How to Cite

Drumond, M. S. F., Machado, L. I. A., Souza, M. C. de, & Souza, S. F. de. (2023). Attention Deficit Hyperactivity Disorder (ADHD): characteristics, diagnosis and treatment with methylphenidate. Revista Brasileira De Educação E Saúde, 13(3), 538–544. https://doi.org/10.18378/rebes.v13i3.10106

Issue

Section

ARTICLES

Most read articles by the same author(s)